Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15152173 | 1.00 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL10335813 | 1.00 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ether SCHEMBL9546497 | 0.95 | LMNA (0.38) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL15966786 | 0.94 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL8332379 | 0.94 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL23497303 | 0.93 | LMNA (0.37) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL528201 | 0.85 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3645857 | 0.84 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9344449 | 0.84 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL27812284 | 0.81 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740212-A2 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp & Dohme Corp. (US) | 2020-11-25 | — | — | EP | claimed |
| US-9114176-B2 | Exogenously triggered controlled release materials and uses thereof | SMARTCELLS, INC. (US) | 2015-08-25 | — | — | US | claimed |
| US-8940690-B2 | Synthetic conjugates and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2015-01-27 | — | — | US | claimed |
| US-20140342980-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS INC (US) | 2014-11-20 | — | — | US | claimed |
| US-8846103-B2 | Exogenously triggered controlled release materials and uses thereof | SMARTCELLS, INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20140256622-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-20140121159-A1 | TERMINALLY–FUNCTIONALIZED CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2014-05-01 | — | — | US | claimed |
| US-20140037699-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2014-02-06 | — | — | US | claimed |
| US-8623345-B2 | Terminally-functionalized conjugates and uses thereof | Smartcells (US) | 2014-01-07 | — | — | US | claimed |
| US-8569231-B2 | Soluble non-depot insulin conjugates and uses thereof | SMARTCELLS, INC. (US) | 2013-10-29 | — | — | US | claimed |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | claimed |
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| WO-2010107519-A1 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088276-A2 | POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088268-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| EP-0576691-B1 | Detergent composition | LION CORP (JP) | 1998-01-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SLC2A4, SLC2A8, CD44 | LMNA 4457/4885L3MBTL1 1047/4885TDP1 2864/4885 |
| US-20140037699-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | LMNA 3585/4885L3MBTL1 1824/4885TDP1 4547/4885 |
| US-20140121159-A1 | TERMINALLY–FUNCTIONALIZED CONJUGATES AND USES THEREOF | NPY1R, NTSR1, GRPR | LMNA 1066/4885L3MBTL1 2061/4885TDP1 1283/4885 |
| US-20140342980-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | LMNA 1669/4885L3MBTL1 295/4885TDP1 2800/4885 |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | LMNA 1669/4885L3MBTL1 295/4885TDP1 2800/4885 |
| US-20140256622-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | CD63, EPHA2, CNDP2 | LMNA 2715/4885L3MBTL1 3117/4885TDP1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.